Development
Vera Therapeutics, Inc.
VERA
$20.64
$0.190.93%
NASDAQ
| 09/30/2023 | 06/30/2023 | 03/31/2023 | 12/31/2022 | 09/30/2022 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 1.22% | 16.06% | 37.52% | 80.19% | 51.52% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -13.82% | 45.91% | 83.64% | 102.48% | 248.10% |
| Operating Income | 13.82% | -45.91% | -83.64% | -102.48% | -248.10% |
| Income Before Tax | 18.54% | -35.74% | -76.00% | -92.56% | -224.25% |
| Income Tax Expenses | -- | -- | -- | 0.00% | -- |
| Earnings from Continuing Operations | 18.54% | -35.74% | -76.00% | -92.55% | -224.25% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 18.54% | -35.74% | -76.00% | -92.55% | -224.25% |
| EBIT | 13.82% | -45.91% | -83.64% | -102.48% | -248.10% |
| EBITDA | -- | -- | -- | -102.60% | -250.34% |
| EPS Basic | 50.02% | 16.97% | -13.20% | -47.75% | -153.37% |
| Normalized Basic EPS | 49.65% | 15.61% | -15.14% | -49.65% | -163.90% |
| EPS Diluted | 50.02% | 16.97% | -13.20% | -47.75% | -153.37% |
| Normalized Diluted EPS | 49.65% | 15.61% | -15.14% | -49.65% | -163.90% |
| Average Basic Shares Outstanding | 63.01% | 63.49% | 55.48% | 30.32% | 27.98% |
| Average Diluted Shares Outstanding | 63.01% | 63.49% | 55.48% | 30.32% | 27.98% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |